Posttreatment changes in cytokines induced by Schistosoma mansoni egg and worm antigens: Dissociation of immunity- and morbidity-associated type 2 responses

Journal of Infectious Diseases

Volumn 209, Issue 11, 2014, Pages 1792-1800

  Wilson, Shona ^a   Jones, Frances M ^a   Kenty, Lee Carol ^a   Mwatha, Joseph K ^b   Kimani, Gachuhi ^b   Kariuki, H Curtis ^c,d   Dunne, David W ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c MINISTRY OF HEALTH   (Kenya)

^d KENYA METHODIST UNIVERSITY   (Kenya)

Author keywords

cytokine; human; immunity; immunopathology; praziquantel; Schistosoma mansoni

Indexed keywords

INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; PARASITE ANTIGEN; PRAZIQUANTEL; RANTES; SOLUBLE EGG ANTIGEN; SOLUBLE WORM ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD CULTURE; CHILD; CONTROLLED STUDY; CYTOKINE RESPONSE; FECES ANALYSIS; FEMALE; FOLLOW UP; HUMAN; KENYA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PARASITE PREVALENCE; PARASITE TRANSMISSION; PRIORITY JOURNAL; SCHISTOSOMIASIS MANSONI;

CYTOKINE; HUMAN; IMMUNITY; IMMUNOPATHOLOGY; PRAZIQUANTEL; SCHISTOSOMA MANSONI;

ADOLESCENT; ANIMALS; ANTIGENS, HELMINTH; CHILD; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; OVUM; PRAZIQUANTEL; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SCHISTOSOMICIDES;

EID: 84900543891     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit826     Document Type: Article

References (33)

1. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 2005; 365: 1561-9.
2. Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. Nat Rev Immunol 2002; 2: 499-511.
3. Colley DG, Barsoum IS, Dahawi HS, Gamil F, Habib M, el Alamy MA. Immune responses and immunoregulation in relation to human schistosomiasis in Egypt. III. Immunity and longitudinal studies of in vitro responsiveness after treatment. Trans R Soc Trop Med Hyg 1986; 80: 952-7.
4. Grogan JL, Kremsner PG, Deelder AM, Yazdanbakhsh M. Antigenspecific proliferation and interferon-gamma and interleukin-5 production are down-regulated during Schistosoma haematobium infection. J Infect Dis 1998; 177: 1433-7.
5. Coutinho HM, Acosta LP, Wu HW, et al. Th2 cytokines are associated with persistent hepatic fibrosis in human Schistosoma japonicum infection. J Infect Dis 2007; 195: 288-95.
6. de Jesus AR, Magalhaes A, Miranda DG, et al. Association of type 2 cytokines with hepatic fibrosis in human Schistosoma mansoni infection. Infect Immun 2004; 72: 3391-7.
7. Alves Oliveira LF, Moreno EC, Gazzinelli G, et al. Cytokine production associated with periportal fibrosis during chronic schistosomiasis mansoni in humans. Infect Immun 2006; 74: 1215-21.
8. Mwatha JK, Kimani G, Kamau T, et al. High levels of TNF, soluble TNF receptors, soluble ICAM-1, and IFN-gamma, but low levels of IL-5, are associated with hepatosplenic disease in human schistosomiasis mansoni. J Immunol 1998; 160: 1992-9.
9. Wilson S, Jones FM, Mwatha JK, et al. Hepatosplenomegaly is associated with low regulatory and Th2 responses to schistosome antigens in childhood schistosomiasis and malaria coinfection. Infect Immun 2008; 76: 2212-8.
10. Joseph S, Jones FM, Kimani G, et al. Cytokine production in whole blood cultures from a fishing community in an area of high endemicity for Schistosoma mansoni in Uganda: the differential effect of parasite worm and egg antigens. Infect Immun 2004; 72: 728-34.
11. Walter K, Fulford AJ, McBeath R, et al. Increased human IgE induced by killing Schistosoma mansoni in vivo is associated with pretreatment Th2 cytokine responsiveness to worm antigens. J Immunol 2006; 177: 5490-8.
12. Wilson S, Jones FM, Fofana HK, et al. Rapidly boosted plasma IL-5 induced by treatment of human Schistosomiasis haematobium is dependent on antigen dose, IgE and eosinophils. PLoS Negl Trop Dis 2013; 7:e2149.
13. Fitzsimmons CM, Jones FM, Pinot de Moira A, et al. Progressive crossreactivity in IgE responses: an explanation for the slow development of human immunity to schistosomiasis? Infect Immun 2012; 80: 4264-70.
14. Grogan JL, Kremsner PG, Deelder AM, Yazdanbakhsh M. Elevated proliferation and interleukin-4 release from CD4+ cells after chemotherapy in human Schistosoma haematobium infection. Eur J Immunol 1996; 26: 1365-70.
15. van den Biggelaar AH, Borrmann S, Kremsner P, Yazdanbakhsh M. Immune responses induced by repeated treatment do not result in protective immunity to Schistosoma haematobium: interleukin (IL)-5 and IL-10 responses. J Infect Dis 2002; 186: 1474-82.
16. Joseph S, Jones FM, Walter K, et al. Increases in human T helper 2 cytokine responses to Schistosoma mansoni worm and worm-tegument antigens are induced by treatment with praziquantel. J Infect Dis 2004; 190: 835-42.
17. Dessein A, Kouriba B, Eboumbou C, et al. Interleukin-13 in the skin and interferon-gamma in the liver are key players in immune protection in human schistosomiasis. Immunol Rev 2004; 201: 180-90.
18. Vennervald BJ, Kenty L, Butterworth AE, et al. Detailed clinical and ultrasound examination of children and adolescents in a Schistosoma mansoni endemic area in Kenya: hepatosplenic disease in the absence of portal fibrosis. Trop Med Int Health 2004; 9: 461-70.
19. Vennervald BJ, Booth M, Butterworth AE, et al. Regression of hepatosplenomegaly in Kenyan school-aged children after praziquantel treatment and three years of greatly reduced exposure to Schistosoma mansoni. Trans R Soc Trop Med Hyg 2005; 99: 150-60.
20. Kariuki HC, Madsen H, Ouma JH, et al. Long term study on the effect of mollusciciding with niclosamide in stream habitats on the transmission of schistosomiasis mansoni after community-based chemotherapy in Makueni district, Kenya. Parasit Vectors 2013; 6: 107.
21. Booth M, Vennervald BJ, Kabatereine NB, et al. Hepatosplenic morbidity in two neighbouring communities in Uganda with high levels of Schistosoma mansoni infection but very different durations of residence. Trans R Soc Trop Med Hyg 2004; 98: 125-36.
22. van der Kleij D, van den Biggelaar AH, Kruize YC, et al. Responses to Toll-like receptor ligands in children living in areas where schistosome infections are endemic. J Infect Dis 2004; 189: 1044-51.
23. van Liempt E, van Vliet SJ, Engering A, et al. Schistosoma mansoni soluble egg antigens are internalized by human dendritic cells through multiple C-type lectins and suppress TLR-induced dendritic cell activation. Mol Immunol 2007; 44: 2605-15.
24. Everts B, Adegnika AA, Kruize YC, Smits HH, Kremsner PG, Yazdanbakhsh M. Functional impairment of human myeloid dendritic cells during Schistosoma haematobium infection. PLoS Negl Trop Dis 2010; 4:e667.
25. Meurs L, Labuda L, Amoah AS, et al. Enhanced pro-inflammatory cytokine responses following Toll-like-receptor ligation in Schistosoma haematobium-infected schoolchildren from rural Gabon. PLoS One 2011; 6:e24393.
26. Wilson S, Vennervald BJ, Dunne DW. Chronic hepatosplenomegaly in African school children: a common but neglected morbidity associated with schistosomiasis and malaria. PLoS Negl Trop Dis 2011; 5:e1149.
27. van Den Biggelaar AH, Grogan JL, Filie Y, et al. Chronic schistosomiasis: dendritic cells generated from patients can overcome antigenspecific T cell hyporesponsiveness. J Infect Dis 2000; 182: 260-5.
28. Fitzsimmons CM, Jones FM, Stearn A, et al. The Schistosoma mansoni tegumental-allergen-like (TAL) protein family: influence of developmental expression on human IgE responses. PLoS Negl Trop Dis 2012; 6:e1593.
29. Roberts M, Butterworth AE, Kimani G, et al. Immunity after treatment of human schistosomiasis: association between cellular responses and resistance to reinfection. Infect Immun 1993; 61: 4984-93.
30. Fulford AJ, Butterworth AE, Ouma JH, Sturrock RF. A statistical approach to schistosome population dynamics and estimation of the lifespan of Schistosoma mansoni in man. Parasitology 1995; 110(pt 3): 307-16.
31. Shaw MK, Erasmus DA. Schistosoma mansoni: structural damage and tegumental repair after in vivo treatment with praziquantel. Parasitology 1987; 94(pt 2): 243-54.
32. Karanja DM, Hightower AW, Colley DG, et al. Resistance to reinfection with Schistosoma mansoni in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study. Lancet 2002; 360: 592-6.
33. Black CL, Mwinzi PN, Muok EM, et al. Influence of exposure history on the immunology and development of resistance to human schistosomiasis mansoni. PLoS Negl Trop Dis 2011; 4:e637.